Antengene (FRA:722) General and Admin. Expense: €4.43 Mil (TTM As of Dec. 2025)


FRA:722 Antengene Corp Ltd FRA:722
40 GF Score
Price €0.40
GF Value €0.14
! 5 Warning Signs
View Full Analysis

What is Antengene General and Admin. Expense?

Antengene FRA:722 +7.49% 40 General and Admin. Expense is €4.43 Mil as of Dec. 2025. GuruFocus rates FRA:722 with a GF Score™ of 40/100 and a GF Value™ of €0.14. The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Antengene's General and Admin. Expense for the six months ended in Dec. 2025 was €3.00 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €4.43 Mil.

Antengene General and Admin. Expense Related Terms

Antengene General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Antengene's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene General and Admin. Expense Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 23.55 22.62 6.39 5.42 4.44

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 2.32 3.03 1.43 3.00
FRA:722
40GF Score
Antengene Corp Ltd FRA:722
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antengene General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €4.43 Mil mean?
Antengene (FRA:722) has a General and Admin. Expense of €4.43 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Antengene and its competitors.
Is Antengene's General and Admin. Expense too high?
Antengene's current General and Admin. Expense is €4.43 Mil. Overall, Antengene has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's General and Admin. Expense compare to VRTX and REGN?
Antengene's General and Admin. Expense of €4.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Antengene and its competitors. Antengene's current General and Admin. Expense is €4.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current General and Admin. Expense of €4.43 Mil. The stock's GF Value™ is €0.14, compared to a current price of €0.40 — trading 187.1% above its estimated fair value. The current General and Admin. Expense is €4.43 Mil. Antengene's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Antengene (FRA:722), the current General and Admin. Expense is €4.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.40 is trading 187.1% above its estimated GF Value™ of €0.14.

Key valuation signals for FRA:722:

  • General and Admin. Expense: €4.43 Mil
  • GF Value™: €0.14 vs. price of €0.40 (187.1% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
40GF Score

Get the complete analysis for FRA:722

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price
€0.14
GF Value